IL-25 blockade augments antiviral immunity during respiratory virus infection

Commun Biol. 2022 May 4;5(1):415. doi: 10.1038/s42003-022-03367-z.

Abstract

IL-25 is implicated in the pathogenesis of viral asthma exacerbations. However, the effect of IL-25 on antiviral immunity has yet to be elucidated. We observed abundant expression and colocalization of IL-25 and IL-25 receptor at the apical surface of uninfected airway epithelial cells and rhinovirus infection increased IL-25 expression. Analysis of immune transcriptome of rhinovirus-infected differentiated asthmatic bronchial epithelial cells (BECs) treated with an anti-IL-25 monoclonal antibody (LNR125) revealed a re-calibrated response defined by increased type I/III IFN and reduced expression of type-2 immune genes CCL26, IL1RL1 and IL-25 receptor. LNR125 treatment also increased type I/III IFN expression by coronavirus infected BECs. Exogenous IL-25 treatment increased viral load with suppressed innate immunity. In vivo LNR125 treatment reduced IL-25/type 2 cytokine expression and increased IFN-β expression and reduced lung viral load. We define a new immune-regulatory role for IL-25 that directly inhibits virus induced airway epithelial cell innate anti-viral immunity.

MeSH terms

  • Antiviral Agents / pharmacology
  • Asthma* / metabolism
  • Humans
  • Immunity, Innate
  • Interleukin-17 / immunology*
  • Rhinovirus
  • Virus Diseases*

Substances

  • Antiviral Agents
  • IL25 protein, human
  • Interleukin-17